Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : PA5108
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : IUVO
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : HPAPI
Upfront Cash : Inapplicable
May 09, 2025
Lead Product(s) : PA5108
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : IUVO
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PA5436
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 09, 2025
Lead Product(s) : PA5436
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Medical Research Future Fund
Deal Size : $1.5 million
Deal Type : Funding
PolyActiva Wins $1.5M Grant for Ocular Implant in Glaucoma Treatment
Details : The company will use the grant funding to advance the PA5346 (latanoprost) second-generation -releasing ocular implant, which is being evaluated for treatment of Glaucoma.
Product Name : Undisclosed
Product Type : HPAPI
Upfront Cash : Undisclosed
July 05, 2024
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Medical Research Future Fund
Deal Size : $1.5 million
Deal Type : Funding
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PA5108 Ocular Implant with Prezia™ technology are being developed to offer a safe and effective, fully biodegradable therapy, which is investigated for the treatment of mild to moderate glaucoma.
Product Name : Undisclosed
Product Type : HPAPI
Upfront Cash : Inapplicable
February 11, 2023
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levofloxacin
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Levofloxacin Ocular Implant in Patients Undergoing Routine Bilateral Cataract Surgery
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
July 01, 2022
Lead Product(s) : Levofloxacin
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of a Latanoprost Ocular Implant for Treatment of Open Angle Glaucoma or Ocular Hypertension.
Details : Undisclosed
Product Name : Undisclosed
Product Type : HPAPI
Upfront Cash : Inapplicable
April 19, 2022
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Phase IIa study met primary and secondary efficacy endpoints of at least 20% IOP lowering in its low dose cohort, demonstrating a potential significant benefit of the PA5108 Ocular Implant designed to treat patients with glaucoma by enabling a constant d...
Product Name : Undisclosed
Product Type : HPAPI
Upfront Cash : Inapplicable
April 03, 2022
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PolyActiva Announces Positive Phase IIa Results for PA5108 Ocular Implant
Details : PA5108 Ocular Implant with Prezia™ technology are being developed to offer a safe and effective, fully biodegradable therapy, which is investigated for the treatment of Open-Angle Glaucoma .
Product Name : Undisclosed
Product Type : HPAPI
Upfront Cash : Inapplicable
February 17, 2022
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levofloxacin
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Levofloxacin Ocular Implant for Ocular Surgery
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
December 23, 2020
Lead Product(s) : Levofloxacin
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Latanoprost FA SR Ocular Implant is designed to provide a constant daily therapeutic dose of latanoprost free acid (the active ingredient of a commonly prescribed glaucoma eye-drop, Xalatan®) for 6-months.
Product Name : Undisclosed
Product Type : HPAPI
Upfront Cash : Inapplicable
May 11, 2020
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable